DNA hypomethylating drugs in cancer therapy

Cold Spring Harbor Perspectives in Medicine

Volumn 7, Issue 5, 2017, Pages

  Sato, Takahiro ^a   Issa, Jean Pierre J ^a,b   Kropf, Patricia ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DECITABINE; DNA METHYLTRANSFERASE INHIBITOR; GUADECITABINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; COLON CANCER; DISEASE COURSE; DNA METHYLATION; DNA MODIFICATION; ENHANCER REGION; GAIN OF FUNCTION MUTATION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; IMMUNE RESPONSE; MYELOID LEUKEMIA; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); DNA DEMETHYLATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; NEOPLASM;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DNA DEMETHYLATION; HUMANS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85016369807     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a026948     Document Type: Article

References (123)

1. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, et al. 2009. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114: 144–147.
2. Baylin, SB, Jones PA. 2011. A decade of exploring the cancer epigenome—Biological and translational implications. Nat Rev Cancer 11: 726–734.
3. Bejar, R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, et al. 2014. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 124: 2705–2712.
4. Bender, CM, Pao MM, Jones PA. 1998. Inhibition of DNA methylation by 5-aza-2ʹ -deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58: 95–101.
5. Blum, W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, et al. 2007. Phase, I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25: 3884–3891.
6. Blum, W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, et al. 2012. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 119: 6025–6031.
7. Borthakur, G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H. 2008. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49: 690–695.
8. Braun, T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, Bouabdallah K, Vey N, Toma A, Recher C, et al. 2011. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: A phase 2 trial. Blood 118: 3824–3831.
9. Brennan, CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al. 2013. The somatic genomic landscape of glioblastoma. Cell 155: 462–477.
10. Brueckner, B, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, Suhai S, Wiessler M, Lyko F. 2005. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 65: 6305–6311.
11. Brueckner, B, Rius M, Markelova MR, Fichtner I, Hals PA, Sandvold ML, Lyko F. 2010. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol Cancer Ther 9: 1256–1264.
12. Cameron, EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103–107.
13. Champion, C, Guianvarc’h D, Senamaud-Beaufort C, Jurkowska RZ, Jeltsch A, Ponger L, Arimondo PB, GuieyssePeugeot AL. 2010. Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine. PLoS ONE 5: e12388.
14. Chen, RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. 1998. DNA hypomethylation leads to elevated mutation rates. Nature 395: 89–93.
15. Chiappinelli, KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, et al. 2015. Inhibiting, DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162: 974–986.
16. Chueh, AC, Tse JW, Togel L, Mariadason JM. 2015. Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells. Antioxid Redox Signal 23: 66–84.
17. Cohen, AL, Holmen SL, Colman H. 2013. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 13: 345.
18. Daver, N, Kantarjian H, Ravandi F, Estey E, Wang X, GarciaManero G, Jabbour E, Konopleva M, O’Brien S, Verstovsek S, et al. 2015. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30: 268–273.
19. Delhommeau, F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, et al. 2009. Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289–2301.
20. Derissen, EJ, Beijnen JH, Schellens JH. 2013. Concise drug review: Azacitidine and decitabine. Oncologist 18: 619–624.
21. Duvic, M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, et al. 2007. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31–39.
22. Fandy, TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, et al. 2009. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114: 2764–2773.
23. Fenaux, P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, et al. 2009. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higherrisk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10: 223–232.
24. Figueroa, ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. 2010. Leukemic, IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553–567.
25. Filippakopoulos, P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067–1073.
26. Gaidzik, VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, et al. 2012. TET2 mutations in acute myeloid leukemia (AML): Results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 30: 1350–1357.
27. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, et al. 2006. Phase 1/2 study of the combination of 5-aza-2ʹ -deoxycytidine with valproic acid in patients with leukemia. Blood 108: 3271–3279.
28. Glasspool, RM, Brown R, Gore ME, Rustin GJ, McNeish IA, Wilson RH, Pledge S, Paul J, Mackean M, Hall GD, et al. 2014. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2ʹ -deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer 110: 1923–1929.
29. Goll, MG, Kirpekar F, Maggert KA, Yoder JA, Hsieh CL, Zhang X, Golic KG, Jacobsen SE, Bestor TH. 2006. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 311: 395–398.
30. Gore, SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, et al. 2006. Combined, DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66: 6361–6369.
31. Greenberg, PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J. 2013. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma 54: 321–328.
32. Griffiths, EA, Choy G, Redkar S, Taverna P, Azab M, Karpf AR. 2013. SGI-110: DNA methyltransferase inhibitor oncolytic. Drugs Future 38: 535–543.
33. Hellebrekers, DM, Jair KW, Vire E, Eguchi S, Hoebers NT, Fraga MF, Esteller M, Fuks F, Baylin SB, van Engeland M, et al. 2006. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 5: 467–475.
34. Heninger, E, Krueger TE, Lang JM. 2015. Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol 6: 29.
35. Hinoue, T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, et al. 2012. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 22: 271–282.
36. Issa, JP, Kantarjian HM. 2009. Targeting, DNA methylation. Clin Cancer Res 15: 3938–3946.
37. Issa, JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, et al. 2004. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2ʹ -deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635–1640.
38. Issa, JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. 2005. Phase, II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23: 3948–3956.
39. Issa, JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. 2015a. Results of phase 2 randomized study of lowdose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 121: 556–561.
40. Issa, JP, Roboz G, Rizzieri D, Jabbour E, Stock W, O’Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, et al. 2015b. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 16: 1099–1110.
41. Itzykson, R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, et al. 2011. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25: 1147–1152.
42. James, SR, Cedeno CD, Sharma A, Zhang W, Mohler JL, Odunsi K, Wilson EM, Karpf AR. 2013. DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics 8: 849–863.
43. Jelinek, J, Liang S, Lu Y, He R, Ramagli LS, Shpall EJ, Estecio MR, Issa JP. 2012. Conserved, DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique. Epigenetics 7: 1368–1378.
44. Jin, C, Qin T, Barton MC, Jelinek J, Issa JJ. 2015. Minimal role of base excision repair in TET-induced global DNA demethylation in HEK293T cells. Epigenetics 10: 1006–1013.
45. Jones, PA. 2012. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 484–492.
46. Jones, PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128: 683–692.
47. Jones, PA, Taylor SM. 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85–93.
48. Juergens, RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, et al. 2011. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1: 598–607.
49. Kagey, JD, Kapoor-Vazirani P, McCabe MT, Powell DR, Vertino PM. 2010. Long-term stability of demethylation after transient exposure to 5-aza-2ʹ -deoxycytidine correlates with sustained RNA polymerase II occupancy. Mol Cancer Res 8: 1048–1059.
50. Kalac, M, Scotto L, Marchi E, Amengual J, Seshan VE, Bhagat G, Ulahannan N, Leshchenko VV, Temkin AM, Parekh S, et al. 2011. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 118: 5506–5516.
51. Kantarjian, H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, et al. 2006. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106: 1794–1803.
52. Kantarjian, H, Oki Y, Garcia-Manero G, Huang X, O’Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, et al. 2007a. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109: 52–57.
53. Kantarjian, HM, O’Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. 2007b. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: Comparison with historical experience. Cancer 109: 1133–1137.
54. Kantarjian, HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, et al. 2012. Multicenter, randomized, openlabel, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or lowdose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30: 2670–2677.
55. Karpf, AR, Peterson PW, Rawlins JT, Dalley BK, Yang Q, Albertsen H, Jones DA. 1999. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci 96: 14007–14012.
56. Klco, JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, Hundal J, Walker J, Varghese N, ErdmannGilmore P, et al. 2013. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 121: 1633–1643.
57. Knutson, SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP, Copeland RA, et al. 2013. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc, Natl Acad Sci 110: 7922–7927.
58. Kondo, Y, Shen L, Yan PS, Huang TH, Issa JP. 2004. Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci 101: 7398–7403.
59. Kuck, D, Caulfield T, Lyko F, Medina-Franco JL. 2010. Nanaomycin, A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 9: 3015–3023.
60. Kulis, M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, Martinez-Trillos A, Castellano G, Brun-Heath I, Pinyol M, et al. 2012. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 44: 1236–1242.
61. LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. 2009. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2: 67.
62. Langemeijer, SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, et al. 2009. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41: 838–842.
63. Li, Q, Ahuja N, Burger PC, Issa JP. 1999. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 18: 3284–3289.
64. Li, H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, et al. 2014. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5: 587–598.
65. Lin, J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, et al. 2009. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 15: 6241–6249.
66. Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, et al. 2011. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplasticcontrast syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29: 1987–1996.
67. Lund, K, Cole JJ, VanderKraats ND, McBryan T, Pchelintsev NA, Clark W, Copland M, Edwards JR, Adams PD. 2014. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. Genome Biol 15: 406.
68. Matei, D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP. 2012. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 72: 2197–2205.
69. Maunakea, AK, Nagarajan RP, Bilenky M, Ballinger TJ, D’Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, et al. 2010. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466: 253–257.
70. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A III, Diaz E, et al. 2012. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108–112.
71. Meldi, K, Qin T, Buchi F, Droin N, Sotzen J, Micol JB, Selimoglu-Buet D, Masala E, Allione B, Gioia D, et al. 2015. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest 125: 1857–1872.
72. Mohammad, HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, et al. 2015. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 28: 57–69.
73. Navada, SC, Steinmann J, Lubbert M, Silverman LR. 2014. Clinical development of demethylating agents in hematology. J Clin Invest 124: 40–46.
74. Newman, EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, et al. 2015. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2ʹ -deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol 75: 537–546.
75. Noushmehr, H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510–522.
76. Odunsi, K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, et al. 2014. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2: 37–49.
77. Oki, Y, Aoki E, Issa JP. 2007. Decitabine—Bedside to bench. Crit Rev Oncol Hematol 61: 140–152.
78. Oki, Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. 2008. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111: 2382–2384.
79. Pandiyan, K, You JS, Yang X, Dai C, Zhou XJ, Baylin SB, Jones PA, Liang G. 2013. Functional, DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res 41: 3973–3985.
80. Parry, L, Clarke AR. 2011. The roles of the methyl-CpG binding proteins in cancer. Genes Cancer 2: 618–630.
81. Paul, TA, Bies J, Small D, Wolff L. 2010. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 115: 3098–3108.
82. Peart, MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW. 2005. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci 102: 3697–3702.
83. Plass, C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. 2013. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 14: 765–780.
84. Prebet, T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, et al. 2014. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia Intergroup trial E1905. J Clin Oncol 32: 1242–1248.
85. Qin, T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP. 2007. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13: 4225–4232.
86. Qin, T, Jelinek J, Si J, Shu J, Issa JP. 2009. Mechanisms of resistance to 5-aza-2ʹ -deoxycytidine in human cancer cell lines. Blood 113: 659–667.
87. Qin, T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, Shu J, He R, Zhang N, Chung W, et al. 2011. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS ONE 6: e23372.
88. Qin, T, Si J, Raynal NJ, Wang X, Gharibyan V, Ahmed S, Hu X, Jin C, Lu Y, Shu J, et al. 2015. Epigenetic synergy between decitabine and platinum derivatives. Clin Epigenet 7: 97.
89. Ravandi, F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, et al. 2013. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121: 4655–4662.
90. Raynal, NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, Estecio MR, Issa JP. 2012. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 72: 1170–1181.
91. Raynal, NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, et al. 2015. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Res 76: 1494–1505.
92. Roulois, D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, et al. 2015. DNAdemethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162: 961–973.
93. Sekeres, MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, et al. 2012. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 120: 4945–4951.
94. Shen, L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, Shu J, Chen X, Waterland RA, Issa JP. 2007a. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet 3: 2023–2036.
95. Shen, L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, et al. 2007b. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci 104: 18654–18659.
96. Si, J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP. 2010. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res 70: 6968–6977.
97. Silverman, LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, et al. 2002. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20: 2429–2440.
98. Silverman, LR, Fenaux P, Mufti GJ, Santini V, HellstromLindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. 2011. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 117: 2697–2702.
99. Smith, ZD, Meissner A. 2013. DNA methylation: Roles in mammalian development. Nat Rev Genet 14: 204–220.
100. Stewart, DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. 2009. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15: 3881–3888.
101. Taby, R, Issa JP. 2010. Cancer epigenetics. CA Cancer J Clin 60: 376–392.
102. TCGA. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330–337.
103. TCGA. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368: 2059–2074.
104. Toyota, M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. 1999. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci 96: 8681–8686.
105. Traina, F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O’Keefe CL, et al. 2014. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 28: 78–87.
106. Treppendahl, MB, Kristensen LS, Gronbaek K. 2014. Predicting response to epigenetic therapy. J Clin Invest 124: 47–55.
107. Tsai, HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al. 2012. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430–446.
108. Turcan, S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479–483.
109. Varley, KE, Gertz J, Bowling KM, Parker SL, Reddy TE, PauliBehn F, Cross MK, Williams BA, Stamatoyannopoulos JA, Crawford GE, et al. 2013. Dynamic, DNA methylation across diverse human cell lines and tissues. Genome Res 23: 555–567.
110. Voso, MT, Fabiani E, Piciocchi A, Matteucci C, Brandimarte L, Finelli C, Pogliani E, Angelucci E, Fioritoni G, Musto P, et al. 2011. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. Leukemia 25: 1910–1913.
111. Weisenberger, DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al. 2006. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787–793.
112. Whittaker, SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, et al. 2010. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28: 4485–4491.
113. Wienholz, BL, Kareta MS, Moarefi AH, Gordon CA, Ginno PA, Chedin F. 2010. DNMT3L modulates significant and distinct flanking sequence preference for DNA methylation by DNMT3A and DNMT3B in vivo. PLoS Genet 6: e1001106.
114. Wijermans, P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A. 2000. Low-dose 5-aza-2ʹ -deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18: 956–962.
115. Williams, K, Christensen J, Helin K. 2012. DNA methylation: TET proteins-guardians of CpG islands? EMBO Rep 13: 28–35.
116. Wrangle, J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, et al. 2013. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4: 2067–2079.
117. Xu, W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu LX, et al. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutaratedependent dioxygenases. Cancer Cell 19: 17–30.
118. Yagi, K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T, Midorikawa Y, Nishimura Y, Sakamoto H, Seto Y, et al. 2010. Three, DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 16: 21–33.
119. Yamazaki, J, Jelinek J, Lu Y, Cesaroni M, Madzo J, Neumann F, He R, Taby R, Vasanthakumar A, Macrae T, et al. 2015. TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor binding sites in chronic myelomonocytic leukemia. Cancer Res 75: 2833–2843.
120. Yamazaki, J, Taby R, Jelinek J, Raynal NJ, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, et al. 2016. Hypomethylation of TET2 target genes identifies a curable subset of acute myeloid leukemia. J Natl Cancer Inst 108.
121. Yang, X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. 2014. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 26: 577–590.
122. Yang, L, Rau R, Goodell MA. 2015. DNMT3A in haematological malignancies. Nat Rev Cancer 15: 152–165.
123. Zhou, L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. 2002. Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321: 591–599.